in-PharmaTechnologist.com presents its periodic round-up of personnel changes in pharmaceutical manufacturing and development.
InSite Vision has appointed Surendra Patel to the newly created position of vice president of operations.
Patel will be responsible for the strategic direction and oversight of operational activities, including the on-site production of clinical supplies for testing product candidates.
He has over 30 years of developmental and operational experience in the pharmaceutical industry.
Canada-based specialty bio-therapeutics company Haemacure has appointed Kenneth Smith to the post of director of manufacturing. In addition the company has also appointed Dawn Benson as its director of quality control and quality assurance.
Benson and Smith have 10 and 15 years experience respectively in their fields. Haemacure has also strengthened its production and laboratory teams at manufacturing facility located in Sarasota, Florida.
US-based anti-infective specialist Oculus has appointed Michelle Carpenter to the position of vice president of regulatory affairs and quality. In the role Carpenter will manage the company's regulatory activities including key negotiations with the FDA.
Carpenter has15 years of experience in regulatory affairs, project management and compliance, including time as vice president of regulatory and medical affairs at Dey.
Biopharmaceutical company Cell Therapeutics has appointed Craig Philips to the post of president, giving him direct responsibility for all development and commercial operations.
Philips was most recently vice president and general manager of Bayer Healthcare Oncology and he has also held posts at Berlex Oncology and Schering-Plough.
Robert Lee has been appointed to the post of vice president, pharmaceutical development at US-based Particle Sciences.
Lee has more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents, most recently as vice president of pharmaceutical development at Novavax.
Danish drugmaker Lundbeck has appointed Ulf Wiinberg as its new chief executive officer and tasked him with finding a replacement for the company's blockbuster antidepressant Cipralex (escitalopram).
Wiinberg was previously employed at Wyeth where he was president of the company's operations in Europe, Middle East, Africa and Canada.
US-based Elite Pharmaceuticals has appointed Stuart Apfel to the post of chief scientific officer, in which capacity he will oversee all scientific activities at the company.
Apfel's previous post was chief medical officer at Elite and he is also founder and current president of US-based consulting firm, Parallax Clinical Research.